⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 21, 2024Clinical Infectious Diseases

Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa

Betty Mwesigwa Fredrick Sawe Janet Oyieko Joel Mwakisisile Edna Viegas Akindiran Akintunde Josphat Kosgei Afoke Kokogho Nyanda Elias Ntinginya Ilesh Jani Georgi Shukarev Jay W. Hooper Steven A. Kwilas Lucy Ward Janice M. Rusnak Callie E. Bounds Rachel Overman Christopher S. Badorrek Leigh Anne Eller Michael A. Eller Christina S. Polyak Amber Moodley C. Lang Tran Margaret C. Costanzo David J. Leggat Dominic Paquin‐Proulx Prossy Naluyima Dickson Anumendem Auguste Gaddah Kerstin Lühn Jenny Hendriks Chelsea McLean Macaya Douoguih Hannah Kibuuka Merlin L. Robb Cynthia Robinson Julie A. Ake

View at Publisher

Ask AI

Bookmark

Share

Abstract

Shorter prophylactic vaccine schedules may offer more rapid protection against Ebola in resource-limited settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mwesigwa et al. (2024) studied this question.

synapsesocial.com/papers/68e6e3e8b6db64358765f730 https://doi.org/10.1093/cid/ciae215

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial2024 · 5 citations
2A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaksEarly-Phase Clinical Trial · 2016 · 63 citations
3Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials2024 · 21 citations
4Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratoryHuman Clinical Trial · 2023 · 10 citations
5Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo2024 · 5 citations

More related papers

Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques2026
Shielding Africa, Protecting the World: Unleashing the Power of Preventative Use of Ebola Vaccines2024
Immunogenicity and safety of Ebola vaccines in children: A systematic review and meta-analysis2025

More from Clinical Infectious Diseases

At Home in the HeartlandWed,
Infected With the Clinical BugWed,